The new data highlight the potential of AstraZeneca’s innovative therapies to improve outcomes across multiple cancer types
Durvalumab in combination with carboplatin and paclitaxel is indicated for the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy
Tremelimumab (Imjudo) in combination with Durvalumab (Imfinzi) is indicated for the treatment of patients with unresectable hepatocellular carcinoma
Presidential Symposium for NIAGARA will highlight practice-changing impact of a perioperative Imfinzi-based regimen in bladder cancer
Back-to-back plenary presentations for LAURA and ADRIATIC Phase III trials reinforce the potential of Tagrisso and Imfinzi in early lung cancer settings
Very strong revenue and EPS growth in the first quarter coupled with exciting pipeline delivery
The British-Swedish pharma major certainly has a strong competitive edge for BTC treatment in the country
Durvalumab in combination with chemotherapy is indicated for the treatment of patients with locally advanced or metastatic biliary tract cancer
The interim data combines three mRNAs into one therapy injected directly into the tumour
Subscribe To Our Newsletter & Stay Updated
